Incyte
| Public | |
| Traded as | NASDAQ: INCY |
| Industry | pharmaceutical company |
| Founded | 1991 |
| Headquarters | Wilmington, Delaware, United States |
|
Key people
|
Hervé Hoppenot (President and CEO, 2014) |
| Revenue | ~US$94.5 million (2011) |
| ~(US$186.5 million) (2011) | |
| Total assets | ~US$329 million (2011) |
| Total equity | ~(US$227 million) (2011) |
|
Number of employees
|
~600[1] |
| Website | www.incyte.com |
| Footnotes / references [2] |
|
Incyte, Corp is a pharmaceutical company based in Alapocas, Delaware.[3] Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi.[3] The company was founded in Palo Alto, California in 1991 and went public in 1993.[1]
The company is working on an investigational Phase III drug for rheumatoid arthritis in partnership with Eli Lilly, called baricitinib.[4]
Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma[5]
History
In 2014, Incyte named Hervé Hoppenot president and CEO.[6] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[6]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[7]
References
- ↑ 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 6.0 6.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.genengnews.com/gen-news-highlights/incyte-to-co-develop-hengrui-s-shr-1210-in-up-to-795m-deal/81251695/
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
